### MEDICAID DRUG REBATE PROGRAM

Release Number 56

\* \* \* IMMEDIATE ATTENTION REQUIRED \* \* \*

NOTE TO: All State Medicaid Directors

# HCFA'S IMPLEMENTATION OF FINAL DECISIONS OF THE REMITTANCE ADVICE REPORT (RAR) WORKGROUP

The RAR Workgroup has completed its tasks and HCFA hereby implements the workgroup's final recommendations.

PRIOR PERIOD ADJUSTMENTS (PPA) - A workgroup decision was previously implemented in Release Number 53, dated August 16, 1995, regarding PPAs. However, a few States have concerns regarding the revised process for PPAs and its effect on their systems. Some labelers voiced that they would still like to see what the State believes to be PPAs. Although the decision regarding how PPAs are handled has not changed, the workgroup wanted to accommodate both parties. Therefore, States can opt to attach a listing of PPAs to their invoice for informational purposes only. Any dollar amount associated with the PPA listing should NOT be part of the dollars claimed on the invoice. (NOTE: Labelers are not obligated to respond to any PPAs incorporated into the State's invoice.)

This PPA list should match what the labeler submits to you as PPAs, with the following exception. There are instances when the labeler incurs a pricing change, reports it to HCFA as required, but the change is not received by HCFA before the deadline for processing the unit rebate amount (URA) tape sent to you. When this occurs, the PPAs submitted to you by the labelers will not match your records. HCFA's next quarterly tape should be used to verify the PPAs submitted to you by the labeler. Please remember that labelers are required to remit rebates using the correct URA.

Any discrepancies between your listing and what the labeler submits to you as PPAs should be discussed with the labeler. Any discrepancies in the URA which can not be settled via discussions with the labeler or review of the HCFA tapes should be directed to HCFA.

2. RAR - The RAR has been revised and renamed to better describe its purpose. The form which labelers will use to uniformly notify and explain the remittance of rebate payments to States is now called the Reconciliation of State Invoice (ROSI). The ROSI was developed to accompany the labeler's payment in response to the State's current quarter invoice only; therefore, retroactive use of the ROSI is prohibited.

Because the original RAR did not meet the needs of labelers or States regarding prior quarter adjustment activity, and because spacing does not allow for such incorporation on the ROSI, a second form has been developed. This form, the Prior Quarter Adjustment Statement (PQAS) will be used by labelers to uniformly reconcile and explain <a href="mailto:prior">prior</a> quarter actions/payments only. Prior quarter actions include reconciling unit changes received from the State, revising previously disputed units, and PPAs.

<u>Draft</u> copies of the ROSI and the PQAS, their instructions, electronic fields, data element definitions, and adjustment/dispute codes are attached for your information. This material will be sent to all labelers informing them that they may optionally begin using the ROSI and the PQAS until HCFA receives forms approval from the Office of Management and Budget (OMB). Once OMB approval is received, the ROSI and the PQAS will be mandatory.

- a. **PROGRAM DEFINITIONS** Because there have been varying definitions and uses of the terms "adjustment" and "dispute," the following definitions of these terms are officially adopted. (The official definition of PPAs is contained in Release Number 53.)
  - Adjustment A correction in the number of units for any given NDC, or a correction to the rebate per unit (RPU) by the labeler for any given NDC. (NOTE: The terms RPU and URA are synonymous.)

Corrections to the number of units invoiced and the RPU can be made by the labeler for various reasons as described in the Adjustment/Dispute Code list for the ROSI/PQAS.

Corrections to the number of units (utilization changes) can be made by the State via a subsequent invoice. Among other reasons, these changes may be caused by:

- 1. Pharmacy providers billing on the wrong NDC;
- 2. Pharmacy providers billing quantity of units improperly; or
- 3. A programming error.

Corrections to the RPU by the labeler may be caused by such things as:

- 1. Changes in AMP and/or BP from those previously reported;
- 2. Price changes incorrectly reported to HCFA; or
- 3. Zero RPU reported by a State.
- Dispute A disagreement between the labeler and the State regarding the number of units the State invoiced for any given quarter. The actual number of units disputed is the difference between those invoiced by the State and those which the labeler is paying for, after any adjustments.

Disputes are initiated by the labeler for various reasons as described in the Adjustment/Dispute Code list for the ROSI/PQAS. The disputed units must be NDC and reason specific. Dollar amounts associated with disputed units accrue interest. (The Dispute Resolution Process is set forth in State Release Number 45.)

Questions regarding implementation of the workgroup's decisions should be directed to Sue Williams on 410-786-3334.

### DRUG LABELER REINSTATEMENTS

Chemrich Laboratories, Incorporated (Labeler Code 10235) and Xactdose, Incorporated (Labeler Code 50962) have submitted missing drug prices for all quarters and signed new rebate agreements. Both labelers' next period of participation in the drug rebate program will begin on January 1, 1996.

## NEW LABELERS

The following labelers have entered into drug rebate agreements and will join the rebate program on January 1, 1996:

Akorn Manufacturing Incorporated (Labeler Code 11098);

Purdue Pharma L.P. (Labeler Code 59011);

PolyMedica Pharmaceuticals Incorporated (Labeler Code 61451);

Faulding Pharmaceutical Company (Labeler Code 61703);

Salix (Labeler Code 62022); and

## LABELER TERMINATIONS

The following labelers are being terminated effective January 1, 1996 for failure to submit pricing data:

C.O. Truxton, Incorporated (Labeler Code 00463);

Coloplast Corporation (Labeler Code 62123).

Bolan Pharmaceuticals, Incorporated (Labeler Code 44437);

LNK International, Incorporated (Labeler Code 50844);

Henley Healthcare/Division of Maxxim Medical, Incorporated (Labeler Code 57437);

Johnson Laboratories, Incorporated (Labeler Code 58118);

Ampharco USA (Labeler Code 59015);

Topi-Cana Specialty Products (Labeler Code 59197); and

Venture Pharmaceuticals (Labeler Code 59785).

Shionogi USA, Incorporated (Labeler Code 45809) has requested termination from the rebate program. This labeler will terminate effective January 1, 1996.

### OTHER ATTACHMENTS

Copies of the topic index and the latest listing of the 90-day treasury bill auction rates for the period of January 3, 1995 through November 20, 1995 are attached.

# Page 5 - Medicaid Drug Rebate Program Release Number 56

Please remember to direct your drug rebate questions to a staff member on the listing we provided with release number 53.

Sally K. Richardson Director Medicaid Bureau

# 3 Attachments

cc:

All State Technical Contacts

All Regional Administrators

All Associate Regional Administrators, Division of Medicaid

# TOPICAL INDEX - STATE MEDICAID RELEASES 1 - 56

TOPIC	RELEASE #
1A Dropa Ligting	11
1A Drug Listing	40
Additional Copies of Releases to SMDs	
Bankruptcy - Drug Labelers	19
Best Price to DSH Covered Entities	36
Betaseron - Coverage & Reimbursement	38-40
Bulk Transfer/Buy-Out of Major Pharm. Assets	54-55
Caverject Coverage	55
Confidential Information Release	17
Constant Disputes by Drug Labelers	23
CPIU Information	9
Dataset Name Changes on Quarterly Rebate Tapes	41
Drug Efficacy Study & Implementation (DESI)	
Change Effective Date	20
Change Schedule	18
Effective Date Revisions	23-24
Dipyridamole Issue	26
Dispute Resolution	
Definition	19
Issues	55
Process Stages	45
Workgroup Survey Results	42
Duplicate Discount/Rebate Mechanism Implementatio	
Enteral Nutritional Products - Coverage	30
Enteral Products	19
Experimental Drugs - Coverage	43
Hotline	53
Index for Drug Rebate Notes	31
Interest Calculation under Section V(b)	29
Invoices	
Correct Labeler Address	36
Incomplete Drug Labeler Data	18
Incorrect Invoicing	26
Remittance Advice Report Survey	35
Submission	19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	32
_	33
Late Submission of Quarterly Prices	33 26
LTE/IRS Drugs	20
Magnetic Media	ГО
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15-23
Specification Revision	14
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	
Medical Supplies & Devices	3-16-26
Metric Conversion/Rounding	18

New Drug Products New Rebate Agreement Status TOPIC	41 23 <b>RELEASE #</b>
OBRA '93 PHS Drug Pricing Program PPAs (Erroneous) - Eli Lilly & Company Prior Authorization Prior Period Adjustments Proposed Discount Equal Access Legislation Publication of Drug Rebate Regulations MB-46-P Quarterly Labeler Contact File Quarterly Reporting - Form HCFA-64, 9r	40 44 37 55 14-16 51 55 26 40
Quarterly Update File Rebates Calculation Formula Less than Administrative Costs Partial Payments Remittance/Check Address	14 7 40 55 30
Rejection of State Records Matching LTE Drugs	41 48-52-53-56 39 38 16
Staff Listing Staff Relocation Standard Summary Record Format State Application of the FUL Program State Contact Information	53 52 13 48 23-26-41
State Coverage LTE & IRS Drugs Unit-Dose Drugs State Data Validation Edits State Hearing Process	40 19 33 44
State Invoices Containing Universal Product Codes State Plan Amendment Requirement State Responsibility - Terminated Drugs State Utilization Data Records - Corrections State Utilization Data Study (SUDS) Tape/Cartridge Return Policy	51 47 19 51 33 19
Tape Submission Checklist Terminated/Deleted Records Termination From Program Timely Receipt of Tapes/Notices of Mailing Tolerance Threshold	30 44 55 45
Clarification For Interest Rebate Amount Adjustments Unit-Dose Packaging Unit Per Package Size	45 48 44 15 3
Unit Rebate Amount (URA) Edits	43

Erroneou	us Amo	ounts	3			5	1
Invoice	when	the	Amount	is	Zero	4	4

TOPIC	ELEASE #
Unit Type	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Revisions	32
UPPS Less Than 1.0	19
Use of Information from Outside Sources	48
Utilization Data	
Corrections/Problems	18
Late Submission	18
Receipt	29-31
Record Format	8-13
Set Naming Requirements	19
Tapes	40
Transmitting Corrections/Adjustments to HCFA	16-40
Vaccine	
Deletions	26
Exclusions	19-23
Policy Clarification	25

(Revised 28 November 1995)

WEEKLY U.S. T-BILL DISCOUNT RATE

The latest weekly 90-day treasury bill auction rates for January 3, 1995 thr

DATE OF AUCTION	TRUE DISCOUNT RATE	
01/03/95	5.947	
01/09/95	6.042	01/17/95
7/95	5.909	03/06/95
7/95	5.731	04/24/95
05/01/95	5.922	
05/08/95	5.806	
05/15/95	5.889	05/22/95
3/95	5.702	07/10/95
1/95	5.600	08/28/95
09/05/95	5.463	
09/12/95	5.504	
09/19/95	5.409	09/25/95
10/30/95	5.450	11/06/95
DATE OF AUCTION	TRUE DISCOUNT RATE	
11/20/955.503		

FAB134:Dmccarthy, 62079. State56.WP